Vycor Medical FY26 Q2 net loss narrows to $2,180; revenue falls 16% to $418,264
Reuters2026/08/14 20:16- Vycor Medical posted revenue of USD 418,264 for the quarter ended June 30, 2026, down 16% year over year.
- Net loss narrowed to USD 2,180 for the six months ended June 30, 2026 from USD 14,676 a year earlier.
- Gross profit fell 17% to USD 344,445, with gross margin easing 2 percentage points to 82%.
- Vycor Medical segment revenue slid 17% to USD 401,224 on lower international sales; NovaVision revenue rose 17% to USD 17,040.
- Cash rose to USD 158,907 at June 30, 2026 from USD 86,982 at Dec. 31, 2025; working capital deficit widened to USD 4.29 million.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Securitize to Help Develop Dubai’s Regulated Tokenized Asset Market
Audley Travel to open concessions in nine John Lewis stores from November 2026
Tessin Nordic Holding announces extraordinary shareholder meeting
Will a 10-year US Treasury yield rising to 5.5% "attack" US stocks? Societe Generale warns: this could be the valuation tipping point.
Bokobza, Global Head of Asset Allocation at Société Générale, pointed out that if the 10-year U.S. Treasury yield reaches 5.5%, corporate profit growth will not be sufficient to offset the impact of rising rates on valuations, and the stock market will face substantial pressure. However, he believes that the upcoming rate hikes by the Federal Reserve and the European Central Bank will be relatively limited and will not disrupt the current economic cycle.
Crypto prices
More
